Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's revenue and growth potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the Class Period [2]. Group 2: Legal Process and Participation - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff, representing the class in the litigation [3]. - A lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. due to misleading statements regarding the competitive position of its product Pylarify, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Lantheus between February 26, 2025, and August 5, 2025, to discuss their legal options [1]. - There is a deadline of November 10, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Lantheus [4]. Group 2: Financial Performance and Impact - Lantheus reported disappointing first-quarter results on May 7, 2025, with Pylarify's performance falling short of market expectations [7]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify's revenue declining by 8.3% year-over-year and a significant reduction in fiscal year 2025 growth projections [7]. - Following these announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [8]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who can adequately represent the class [9]. - Any member of the class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9]. Group 4: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Lantheus' conduct [10].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Lantheus Holdings, Inc. about a class action lawsuit due to alleged false statements regarding the company's revenue outlook and market dynamics [1][3]. Group 1: Allegations - The complaint alleges that Lantheus Holdings made false statements and concealed information about its projected revenue and growth, creating a misleading impression of its market position [3]. - Specifically, the company reportedly overstated the sales growth potential of its product Pylarify and downplayed risks related to competition, pricing, seasonality, and macroeconomic factors [3]. Group 2: Class Action Details - The class period for the lawsuit is from February 26, 2025, to August 5, 2025, and shareholders are encouraged to register for participation by the deadline of November 10, 2025 [3][4]. - Shareholders who register will receive updates on the case's progress and can seek to be appointed as lead plaintiff, although this is not a requirement for recovery [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [3][4][5]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally, with Pylarify being a significant product in its portfolio [2]. Allegations of Misrepresentation - The lawsuit claims that Lantheus's executives created a false impression of the company's revenue projections and growth while downplaying risks from competition and market dynamics [3]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to a lack of accurate understanding of pricing and competitive dynamics [3]. Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, attributing it to a "temporal competitive disruption," and subsequently lowered its full-year growth projections from low-single-digit to mid-single-digit growth to flat-to-low single-digit growth [4]. - Following this announcement, Lantheus's stock price fell by more than 23% [4]. - On August 6, 2025, the company announced further disappointing results, with Pylarify sales down 8.3% year-over-year, leading to a nearly 29% drop in stock price after slashing fiscal year 2025 growth projections [5]. Legal Process for Lead Plaintiff - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Lantheus securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6].

Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)?Did you purchase your shares between February 26, 2025 and August 5, 2025, inclusive?Did you lose money in your investment in Lantheus Holdings, Inc.?Do you want to discuss your rights? NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities f ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-f ...

Group 1 - The Rosen Law Firm is reminding purchasers of Lantheus Holdings, Inc. securities from February 26, 2025, to August 5, 2025, about the lead plaintiff deadline on November 10, 2025 [1] - Investors who purchased Lantheus securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify's competitive position, failing to disclose critical information regarding pricing and market dynamics [5] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [4][5][6]. Group 1: Class Action Details - The class action lawsuit is titled Margolis v. Lantheus Holdings, Inc., and covers purchasers of Lantheus securities from February 26, 2025, to August 5, 2025 [1]. - Investors have until November 10, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Lantheus's executives created a false impression of the company's financial health and growth prospects [4]. Group 2: Allegations and Financial Impact - The lawsuit alleges that Lantheus reported a year-over-year decrease in Pylarify sales due to a "temporal competitive disruption," leading to a significant reduction in growth projections [5]. - Following the disappointing first quarter results announced on May 7, 2025, Lantheus's stock price fell over 23% [5]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, causing the stock price to drop nearly 29% [6]. Group 3: Company Overview - Lantheus develops and commercializes diagnostic and therapeutic products for heart disease, cancer, and other conditions, with Pylarify being a key product in its portfolio [3].

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lantheus-holding ...